GUTS Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.180

-65.38%

-0.170

-65.31%

-0.165

-71.05%

Estimates Revision

The market is revising No Change the revenue expectations for Fractyl Health, Inc. (GUTS) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 42.86%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+3.69%

In Past 3 Month

Stock Price

Go Up

+42.86%

In Past 3 Month

6 Analyst Rating

Wall Street analysts forecast GUTS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GUTS is 6.52 USD with a low forecast of 3.60 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

3.60

Averages

6.52

High

10.00

Current: 0.000

Low

3.60

Averages

6.52

High

10.00

Morgan Stanley

Overweight

downgrade

$10 -> $8

2026-01-08

New

Reason

Morgan Stanley

Price Target

$10 -> $8

2026-01-08

New

downgrade

Overweight

Reason

Morgan Stanley lowered the firm's price target on Fractyl Health to $8 from $10 and keeps an Overweight rating on the shares. The firm sees a continuation of U.S. small-to-mid cap biotech's outperformance in 2026 as commercial names transition from "capital consumers to producers" and Large Cap Biopharma faces a looming patent cliff, the analyst tells investors in an outlook note for the group.

Canaccord

Buy

maintain

$6 -> $8

2025-11-21

Reason

Canaccord

Price Target

$6 -> $8

2025-11-21

maintain

Buy

Reason

Canaccord raised the firm's price target on Fractyl Health to $8 from $6 and keeps a Buy rating on the shares. The firm said the company's 3Q25 report was incremental following REMAIN-1 data in Sept which surprised to the upside. After digesting the data the firm increaed its POS to 70% from 60% and doubling our peak penetration to 2% from 1% for Revita ahead of a catalyst heavy 4Q25/1Q26.

BofA

Jason Gerberry

Buy

maintain

$4 -> $5

2025-09-28

Reason

BofA

Jason Gerberry

Price Target

$4 -> $5

2025-09-28

maintain

Buy

Reason

BofA analyst Jason Gerberry raised the firm's price target on Fractyl Health to $5 from $4 and keeps a Buy rating on the shares. The firm increased the probability of success for Revita to 55% from 20% following the Remain-1 data. The the midpoint analysis of Revita in weight maintenance were better than expected, the analyst tells investors in a research note. The firm says Revita-treated patients lost an additional 2.5% body weight versus sham regaining 10% of body weight at three months and there were no safety red flags.

H.C. Wainwright

Buy

downgrade

$9 -> $8

2025-09-26

Reason

H.C. Wainwright

Price Target

$9 -> $8

2025-09-26

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on Fractyl Health to $8 from $9 and keeps a Buy rating on the shares after Fractyl announced midpoint randomized cohort results from the ongoing REMAIN-1 trial evaluating the Revita DMR procedure for weight loss after GLP-1 RA discontinuation. The change in the firm's target is based primarily on adjustment of the fully diluted share count following the significant September fundraise and increasing the firm's projected chance of success for Revita to 60% from 40% based on the positive REMAIN-1 midpoint cohort efficacy and safety results.

H.C. Wainwright

initiated

2025-09-15

Reason

H.C. Wainwright

Price Target

2025-09-15

initiated

Reason

H.C. Wainwright initiated coverage of Fractyl Health with a Buy rating and $9 price target. Fractyl is a clinical stage biotechnology company focused on developing one-time, long-lasting, disease-modifying treatments for obesity and type 2 diabetes, targeting the gut and the pancreas as the root-cause organs of metabolic diseases, the analyst tells investors in a research note. The firm says Fractyl's Revita and Rejuva have exhibited sustained weight loss and glucose control efficacy, with favorable safety and tolerability profiles.

Ladenburg

initiated

$3.60

2025-08-28

Reason

Ladenburg

Price Target

$3.60

2025-08-28

initiated

Reason

Ladenburg initiated coverage of Fractyl Health with a Buy rating and $3.60 price target. Fractyl is \"advancing a differentiated approach to obesity\" through its Revita duodenal mucosal resurfacing system, which has a \"clearly defined\" clinical development pathway, the analyst tells investors. The REMAIN-1 study will deliver initial readouts in late 2025, followed by pivotal six-month data from the 315-patient trial in the second half of next year, giving Fractyl multiple catalysts into 2026, the analyst added.

Valuation Metrics

The current forward P/E ratio for Fractyl Health Inc (GUTS.O) is -3.31, compared to its 5-year average forward P/E of -1.93. For a more detailed relative valuation and DCF analysis to assess Fractyl Health Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-1.93

Current PE

-3.31

Overvalued PE

-0.62

Undervalued PE

-3.24

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.24

Current EV/EBITDA

-3.07

Overvalued EV/EBITDA

0.18

Undervalued EV/EBITDA

-4.66

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

4900.68

Current PS

0.00

Overvalued PS

10155.91

Undervalued PS

-354.55

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

GUTS News & Events

Events Timeline

No data

News

5.0

01-06NASDAQ.COM

Fractyl Health Appoints Lara Smith Weber as CFO Effective January 12, 2026

7.0

01-05Globenewswire

Fractyl Health Outlines 2026 Strategic Outlook with $85.6 Million Cash Reserves

8.5

2025-12-16Benzinga

Lightwave Logic, Kyverna Therapeutics, and Other Major Stocks Decline in Tuesday's Pre-Market Trading

People Also Watch

Frequently Asked Questions

What is Fractyl Health Inc (GUTS) stock price today?

The current price of GUTS is 2 USD — it has decreased -4.76 % in the last trading day.

What is Fractyl Health Inc (GUTS)'s business?

Fractyl Health, Inc. is a metabolic therapeutics company. The Company is focused on developing new approaches to the treatment of metabolic diseases, including obesity and type 2 diabetes (T2D). The Company’s lead product candidate, Revita, is designed to remodel the duodenal lining via hydrothermal ablation (i.e. duodenal mucosal resurfacing) to reverse damage to intestinal nutrient sensing and signaling mechanisms caused by chronic high-fat and high-sugar diets that are a root cause of metabolic disease. The Revita clinical program is focused on patients living with obesity who want to maintain their weight loss after GLP-1 drug discontinuation. The Company’s Rejuva platform focuses on developing adeno-associated virus (AAV)-based, locally delivered gene therapies for the treatment of obesity and T2D. The Rejuva platform leverages advanced delivery systems and proprietary screening methods to identify and develop metabolically active gene therapy candidates targeting the pancreas.

What is the price predicton of GUTS Stock?

What is Fractyl Health Inc (GUTS)'s revenue for the last quarter?

Fractyl Health Inc revenue for the last quarter amounts to 0.00 USD, decreased -100.00 % YoY.

What is Fractyl Health Inc (GUTS)'s earnings per share (EPS) for the last quarter?

Fractyl Health Inc. EPS for the last quarter amounts to -0.71 USD, increased 47.92 % YoY.

What changes have occurred in the market's expectations for Fractyl Health Inc (GUTS)'s fundamentals?

How many employees does Fractyl Health Inc (GUTS). have?

Fractyl Health Inc (GUTS) has 107 emplpoyees as of January 10 2026.

What is Fractyl Health Inc (GUTS) market cap?

Today GUTS has the market capitalization of 306.74M USD.